NCT03332121View on ClinicalTrials.gov

B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 22, 2018

Primary Completion Date

November 30, 2020

Study Completion Date

February 28, 2021

Conditions
CD20 Positive B Cell Non-Hodgkin's Lymphoma
Interventions
BIOLOGICAL

B001

4 times intravenous injection totally,dosing at Day1,Day35,Day56,Day77

Trial Locations (2)

300020

Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin

Unknown

The second affiliated hospital of Guangzhou medical university, Guangzhou

All Listed Sponsors
lead

Shanghai Pharmaceuticals Holding Co., Ltd

INDUSTRY

NCT03332121 - B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter